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A B S T R A C T
Gaucher disease (GD) is a rare hereditary disorder caused by a deﬁciency of the lysosomal enzyme β-gluco-
cerebrosidase. Diagnosis is challenging owing to a wide variability in clinical manifestations and severity of
symptoms. Many patients may experience marked delays in obtaining a deﬁnitive diagnosis. The two surveys
reported herein aimed to explore the patient journey to diagnosis of GD from the perspectives of Gaucher expert
physicians and patients. Findings from the surveys revealed that many patients experienced diagnostic delays
and misdiagnoses, with nearly 1 in 6 patients stating that they were not diagnosed with GD for 7 years or more
after ﬁrst consulting a doctor. Physicians and patients both reported multiple referrals to diﬀerent specialties
before a diagnosis of GD was obtained, with primary care, haematology/haematology-oncology and paediatrics
the main specialties to which patients ﬁrst presented. Splenomegaly, thrombocytopenia, anaemia and bone pain
were reported as the most common medical problems at ﬁrst presentation in both surveys. These ﬁndings
support a clear need for straightforward and easy-to-follow guidance designed to assist non-specialists to identify
earlier patients who are at risk of GD.
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1. Introduction
Gaucher disease (GD) is a chronic condition caused by a recessively
inherited deﬁciency of the GBA1 gene, which encodes the lysosomal
enzyme β-glucocerebrosidase (glucosylceramidase; EC 3.2.1.45) [1].
The disease is characterised by the accumulation of storage materials,
predominantly glucosylceramide, in the lysosomes of cells of the
monocyte–macrophage system, leading to multi-systemic disease
manifestations including splenomegaly, hepatomegaly, thrombocyto-
penia, anaemia and bone disease [1]. It can be categorised into three
types based primarily on phenotypic diﬀerences; however, a consider-
able overlap of clinical features between types has led to GD being
regarded as a phenotypic continuum [2], with GD types used mainly to
aid management decisions. The most common form seen in Europe and
North America is type 1 GD, which accounts for ~95% of all cases [3,4]
and is conventionally characterised by an absence of early onset pri-
mary central nervous system disease. Types 2 and 3 GD are neurono-
pathic forms of the disease in which the central nervous system is also
aﬀected [1]. Type 2 (acute neuronopathic) GD, the rarest form, af-
fecting< 1% of all GD patients, is characterised by rapid deterioration,
with death usually occurring before 2 years of age, while patients with
type 3 (chronic neuronopathic) GD (~5% of all GD patients) experience
a slower disease course [5].
GD is typically diagnosed via enzyme assay to detect
β-glucocerebrosidase, but patients may be diagnosed by genotype
testing to identify GD-associated GBA1 mutations [1]. A timely and
deﬁnitive diagnosis minimises the impact of misdiagnoses and un-
necessary and invasive diagnostic procedures, and can aid the optimal
management of symptomatic patients [6–9]. Since enzyme replacement
therapies and substrate reduction therapies have been introduced, they
have shown to be eﬀective at preventing and reducing the systemic
manifestations and some complications of type 1 GD, including hepa-
tomegaly, splenomegaly, cytopenia, growth delay and some bone dis-
ease [6,10–15]. Conversely, delay in diagnosis and access to appro-
priate management can potentially increase the risk of irreversible
complications, such as avascular necrosis, in certain symptomatic pa-
tients. No treatment is speciﬁcally approved for the management of the
neurological manifestations of GD.
Diagnosis of GD presents a signiﬁcant challenge to the non-GD
specialist owing to the wide variability in age, severity and type of
clinical manifestations at time of presentation. This is compounded by a
lack of familiarity among physicians with the early clinical features of
the disease because of its low prevalence [6,16]. The earliest presenting
clinical features of GD are often general and non-speciﬁc, such as
nosebleeds, fatigue and pain. Further, while the evaluation of bio-
markers, e.g. chitotriosidase activity or chemokine (C-C motif) ligand
18 (CCL18), have been shown to have potential in initial screening for
GD [17], they are not routinely tested or available in many local la-
boratories. Disease-speciﬁc early presenting features tend to reﬂect the
haematological aspect of the disease; therefore, many patients are in-
itially referred to haematologists. Nevertheless, in a survey of 406
haematologist/oncologists from the US, Argentina, Brazil, Canada,
Japan, Spain and Australia, only 20% considered type 1 GD in their
diﬀerential diagnosis of patients presenting with the classic clinical
features of GD: anaemia, thrombocytopenia, hepatosplenomegaly and
bone pain; physicians were more likely to consider leukaemia, lym-
phoma or multiple myeloma instead [6].
The aim of this article is to examine the patient journey in relation
to the diagnosis of GD from two perspectives: 1) from patients on their
journey towards a diagnosis of GD; and 2) from expert physicians in-
volved in the diagnosis and management of patients with GD.
2. Methods
2.1. GD expert physician survey
The objective of the GD expert physician survey was to examine the
pre-diagnosis period of patients with GD from the perspective of in-
ternational medical experts involved in their care. Sixteen international
GD experts from 12 countries who had expressed interest in screening
for Gaucher disease, through authorship of published literature or in-
volvement in planned or ongoing disease screening studies (irrespective
of funding source), were invited to participate in the survey. Experts
were from multiple specialties, including: haematology (4), paediatrics
(4), genetics (4), metabolism (3), paediatric genetics (1), bone (1), in-
ternal medicine (1), radiology (1) and rheumatology (1) (participants
could have more than one specialty).
The survey was conducted from 25 February to 22 March 2015, and
comprised nine questions: ﬁve regarding the characteristics of the pa-
tient population, which requested demographic information; three
questions regarding patients’ presenting symptoms and patient re-
ferrals, which provided a list of pre-speciﬁed options from which to
choose (with the option to specify “other”); and one question on di-
agnostic delays, which invited a free-text response (Appendix A). The
survey was hosted by SurveyMonkey® (California, US) and was acces-
sible via an online link.
In response to survey questions, experts provided summary data for
all GD patients under their care, irrespective of their present treatment
status or type of treatment received; no individual patient data were
provided. Survey responses were consolidated for comparison between
centres. Responses to questions regarding demographics, referrals and
presenting clinical features were pooled for further analysis of the
larger population.
2.2. GD patient survey (US)
The objective of the survey of patients from this US-based patient
support programme (OnePath®) was to examine the pre-diagnosis
period of patients subsequently diagnosed with type 1 GD and to better
understand the earliest presenting features and the patient journey. The
patient support system, funded by Shire Human Genetic Therapies Ltd.,
provides support to patients with rare diseases, their families and
healthcare providers in the US, and is approved by the US Food and
Drug Administration [18]. All patients enrolled in this support system
provided consent to receive GD-speciﬁc information. Patients with type
1 GD were invited by e-mail to participate anonymously in an online
survey. At the time of invitation, patients were informed that their
anonymised responses could be included in publication(s) intended to
help identify issues in the diagnosis of GD. Participation was voluntary
and did not inﬂuence the services that patients received.
The survey was conducted between 3 and 23 March 2015 using the
CustomerSat™ internet portal (Conﬁrmit, Oslo, Norway) and comprised
13 questions: 12 relating to the pre-diagnosis period (including one
inviting a free-text response) and one relating to current care (Appendix
B). The survey questions were initially designed by the Shire medical
team, with review and input from external GD experts. Anonymised
responses were pooled and tabulated using frequency distribution.
3. Results
3.1. GD expert physician survey
Sixteen medical experts from 14 GD specialist centres across 12
countries participated (Table 1). At the time of the survey, these med-
ical experts were responsible for managing a total of 1595 patients with
GD, of whom 94% had type 1 GD. Of 1540 patients for whom data were
available, 88% were ≥18 years of age at the time the survey took
place, and 55% were of Ashkenazi Jewish ancestry, mainly from sites in
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Israel (Jerusalem, 93%), the US (Washington, DC, 60%), France (Paris,
55%) and the UK (London, 45%).
The results conﬁrmed ﬁndings from the literature that many diﬀerent
medical specialties are involved in the pre-diagnosis period of their pa-
tients with GD. Haematology/haematology-oncology, paediatrics and
primary care were the most cited specialties to which patients ﬁrst pre-
sented with GD-related clinical features (Fig. 1A). The same specialties
also were cited as being involved in a large proportion of patient referrals
to their expert centres, with approximately 31% of 798 patients (12 re-
sponses) referred from haematologists/haematologist-oncologists, 21%
from paediatricians and 9% from primary care physicians.
Splenomegaly was reported as one of the main presenting features
by 11 centres, occurring in 59% of 668 patients, while thrombocyto-
penia was reported as a main feature by 10 centres but occurred in
greater numbers of patients overall (66% of patients). Anaemia was a
main feature in 39% of patients from 10 centres, hepatomegaly in 57%
of patients from nine centres and bone or joint pain in 49% of patients
from nine centres (Fig. 1B).
Experts were asked about the causes of diagnostic delays frequently
experienced by patients. The main causes of diagnostic delays in pa-
tients referred to their centres were cited as lack of awareness of GD/
misdiagnosis (7 [54%] of experts), followed by phenotypic hetero-
geneity/non-speciﬁc symptoms (3 [23%]), mild symptomology (2
[15%]) and outsourced testing (1 [8%]) (Fig. 1C). No speciﬁc data were
collected on the time to diagnosis.
3.2. GD patient survey (US)
Survey responses were provided by 212 of 583 (36%) invited pa-
tients (or patients’ parents), all of whom were located in the US, with a
median (range) age of 50 (5–92) years. Of these, 109 (19%) patients
provided free-text responses on their journey to diagnosis.
Abdominal distension was the most common health problem to be
cited as the ﬁrst clinical feature of type 1 GD that patients recalled ex-
periencing (20%), followed by moderate/severe bleeding (14%) and bone
or joint pain (13%) (Fig. 2). Of the 158 patients who indicated the
specialty from which they ﬁrst sought help for their symptoms, the ma-
jority cited paediatricians (42 [27%] patients), haematologists/haematol-
ogist-oncologists (41 [26%] patients) or primary care physicians (38
[24%] patients) (Fig. 3A). Thirty-ﬁve of the 38 patients who initially
presented to primary care were referred to another specialty, 24 (63%) of
whom were referred to haematologists/haematologist-oncologists
(Fig. 3B). Seventy of 116 (60%) respondents reported that they were
eventually diagnosed by physicians within this specialty (Fig. 3C). The
majority of patients reported that they were diagnosed with GD either as
children (0–9 years, 78 of 212 [37%] responses) or young adults
(19–39 years, 61 of 212 [28%]) (Fig. 4). Most patients (112/154 [73%])
were diagnosed within 1 year of ﬁrst seeing a doctor, but for others
(22/154 [14%]), diagnosis took 7 years or more.
In the free-text responses provided by 109 patients, eight patients
commented that their diagnosis was largely serendipitous, e.g. from a rou-
tine heath check or on the basis of clinical suspicion from their physician,
while 11 patients reported that diagnosis was the result of the previous
diagnosis of an older sibling or, in one case, due to both parents being
known carriers. Eight patients commented on the impact of undiagnosed
disease on their lives during the period leading up to diagnosis, including
reduced quality of life owing to bone pain and chronic fatigue, emotional
distress due to initial suspicions of cancer, and depression and suicidal
thoughts as a result of having no explanation for their symptoms. Twenty-
ﬁve (23%) described experiences of physicians lacking awareness of GD,
with one patient commenting that general practitioners in particular should
be more educated about rare diseases. Fourteen (13%) patients mentioned
receiving previous misdiagnoses, six of whom reported a previous mis-
diagnosis or strong suspicion of cancer (leukaemia, multiple myeloma or
liver cancer). Other misdiagnoses noted were Legg-Calvé-Perthes disease,
Boeck's sarcoid or sarcoidosis, von Willebrand disease, folic acid and B12
deﬁciency, allergies and growing pains. One patient reported “several other
illnesses” while another did not specify the misdiagnosed condition.
4. Discussion
The diagnosis of GD can be particularly challenging to the non-GD
specialist, owing to the variability in the type and severity of presenting
clinical features and patient age at presentation, combined with a lack
of familiarity because of its low prevalence [6,16]. As a result, GD may
not always be considered by non-specialists in their diﬀerential diag-
nosis. Here we review results from surveys of patients and GD expert
physicians in an attempt to understand better the Gaucher patient
journey in the period prior to obtaining a correct diagnosis.
Findings from both the patient and physician surveys reveal that
many patients presenting with clinical features of GD experience di-
agnostic delays and misdiagnoses, while several patients reported
multiple referrals to diﬀerent specialties before obtaining a diagnosis of
GD. This is in agreement with a global survey of patients and haema-
tologist-oncologists, in which patients consulted up to eight physicians
(mean of three) before receiving a diagnosis [6]. Nearly 1 in 6 patients
participating in the US patient survey stated that they did not receive a
diagnosis of GD for 7 years or more after ﬁrst consulting a doctor, in
line with previous reports in which the time from ﬁrst onset of clinical
features to diagnosis ranged from 0.5 to 26 years [6,12,19].
The demographic characteristics of US patients participating in the pa-
tient survey were similar to those previously reported from the International
Collaborative Gaucher Group (ICGG) registry. In the US patient survey, 45%
were diagnosed by the age of 18 years, compared with 56% patients (with
disease onset or diagnosis by the age of 20 years) in the ICGG registry [20].
The main presenting clinical features in patients from the ICGG registry
were splenomegaly (55% with spleen volume 5–15 multiples of normal
[MN]), hepatomegaly (53% with liver volume 1.25–2.5 MN), moderate
thrombocytopenia (50–70% with platelet count ≤60–120× 109/L) and
anaemia (20–30% patients), consistent with ﬁndings from both the physi-
cian and patient surveys. Bone pain was experienced by 38% patients and
bone crisis by 12% patients in the ICGG registry at the time of diagnosis
[20], compared with 13% of patients in the patient survey recalling bone
symptoms at time of presentation.
Although the consistency of these survey ﬁndings with previously
published registry data are reassuring, data from surveys are inherently
limited because of the voluntary nature of participation, leading to
possible bias in the selection of participants as well as the potential for
missing, incomplete or inaccurate responses. This is particularly perti-
nent for those questions relying on patient memory. The US patient
Table 1
Countries and cities of participating GD centres in the physician survey.
Country City Patients with GD (N= 1595)
Total, n GD type, %
1 2 3
Australia Melbourne 26 100 0 0
Brazil Porto Alegre 41 90.3 2.4 7.3
France Marseille
Paris
15
80
100
80
0
5
0
15
Germany Mainz 130 78 2 20
Ireland Dublin 6 83 17 0
Israel Jerusalem 648 98.6 0 1.4
Italy Udine 62 90.3 ND ND
Japan Kumamoto 5 20 80 0
Russia Moscow 260 99 0 1
Spain Barcelona 15 93.3 0 6.7
UK Cambridge
London
149
103
97.3
90.3
0
0
2.7
9.7
US Washington, DC 55 80 5 15
GD, Gaucher disease; ND, no data.
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Fig. 1. Results of the physician survey. Respondents could select> 1
answer. A) Specialties to which patients of Gaucher disease experts
ﬁrst presented with Gaucher disease-related symptoms (41 responses
from 10 centres, 663 patients). B) Main presenting features at di-
agnosis of patients presenting to Gaucher disease experts (75 re-
sponses from 11 centres, 668 patients). C) Main causes of diagnostic
delay in patients presenting to Gaucher disease experts (13 responses
from 11 centres, 736 patients). GD, Gaucher disease.
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survey recruited patients from the OnePath patient support system,
which is funded by Shire and designed to support patients receiving
Shire's approved rare disease products. Therefore, data cannot be ex-
trapolated to the general disease population.
Nonetheless, these ﬁndings support a clear need for straightforward and
easy-to-follow guidance designed to assist non-specialists in diagnosing
symptomatic patients earlier in the course of their disease. A proportion of
patients diagnosed with GD remain asymptomatic [21]. However, for
symptomatic patients a timely and deﬁnitive diagnosis of GD can enable
access to appropriate management, thereby potentially reducing the risk of
unnecessary invasive diagnostic investigations, misdiagnosis and the de-
velopment of irreversible complications. Obtaining a diagnosis in asymp-
tomatic or pre-symptomatic patients through screening is questionable
owing to the unlikelihood that an early diagnosis will impact their man-
agement or disease course. Although the inclusion of GD in newborn
screening panels has been considered in several countries [22–25], the high
cost and potential psychological/emotional impact on patients diagnosed
with adult-onset or mild disease [26] means that newborn screening for GD
remains unlikely to be widely adopted.
A number of consensus diagnostic algorithms have been developed
to aid non-specialists in the diagnosis of GD in symptomatic patients. In
2011, Mistry et al. proposed a straightforward diagnostic algorithm for
patients presenting with splenomegaly and/or thrombocytopenia, with
variations for patients with or without Ashkenazi Jewish heritage [7].
In 2014, Di Rocco et al. proposed an algorithm targeted at haematol-
ogists for the diagnosis of GD in paediatric patients, based on published
studies and data from the ICGG registry [27]. More recently, in 2016,
Elmonem et al. reported on the application of a diagnostic algorithm to
children who were suspected of having a lysosomal storage disorder
[19]. However, while these algorithms oﬀer invaluable guidance to
non-specialists for the diﬀerential diagnosis of patients already sus-
pected of having a lysosomal storage disorder, there is no guidance for
he identiﬁcation of these at-risk individuals.
Motta et al. [16] investigated the impact of applying a previously
published diagnostic algorithm [7] in combination with the dried blood-
spot enzyme test [28] to identify type 1 GD among adults presenting with
unexplained splenomegaly and/or thrombocytopenia, the most common
presentation of the disease [6,27], in Italian haematology units. Considering
only these two parameters, 34 of 196 (17%) patients included in screening
had a positive dried blood-spot result and 7 (4%) were conﬁrmed to have
type 1 GD, indicating that this approach can result in the successful iden-
tiﬁcation of patients with GD by non-specialists.
In an attempt to expand on these ﬁndings, the ﬁrst phase of the
Gaucher Earlier Diagnosis Consensus (GED-C) initiative [29–31] aimed to
identify the presenting signs and patient co-variables that are most in-
dicative of types 1 and 3 GD during the early stages of disease. GED-C is an
ongoing international project that applies Delphi methodology, a widely
accepted technique for gathering and processing data from expert groups
[32], to achieve consensus on aspects relating to the diagnosis and man-
agement of GD [29–31]. Similar methodology has been used previously to
develop a disease severity scoring system for type 1 GD with the aim of
standardising disease monitoring [33]. The GED-C panel consists of 22 GD
experts recognised globally as leading GD experts, and a non-clinical chair
with expertise in the Delphi technique. Using this technique, the panel
reached consensus on the identiﬁcation of clinical signs and co-variables
indicative of types 1 and 3 GD during the early stages of disease, and their
classiﬁcation as major or minor using 5-point Likert scales of importance
(Table 2). The signs and co-variables identiﬁed by this study are consistent
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Delay in starting puberty
Enlarged spleen
Pain/lump felt in abdomen
Slow growth
No health problems, screened
because of family with GD
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Moderate/severe bruising
Bone or joint pain
Moderate/severe bleeding
Abdominal distension
Number of patients
42
29
3
14
2
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6
6
7
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25
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3
Fig. 2. Earliest health problem experienced by patients taking part in
the US patient survey (N= 209). GD, Gaucher disease.
Table 2
Consensus on major signs and co-variables in types 1 and 3 GD (GED-C initiative) [29–31].
Type 1 GD Type 3 GD
Major signs Splenomegaly, thrombocytopenia, anaemia, hepatomegaly, bone issues (pain,
crises, avascular necrosis and fractures), hyperferritinaemia and gammopathy
Splenomegaly, thrombocytopenia, anaemia, hepatomegaly, oculomotor
disturbances, myoclonic epilepsy, bone pain, motor disturbances and
kyphosis
Major co-variables Family history of GD, Ashkenazi Jewish ancestry Family history of GD
GD, Gaucher disease; GED-C, Gaucher Earlier Diagnosis Consensus.
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Fig. 3. Specialties involved in the diagnosis of patients with Gaucher
disease taking part in the US patient survey. (A) Specialty ﬁrst seen
regarding health problems (N= 158). (B) Specialty to which patients
who ﬁrst saw a primary care physician were ﬁrst referred (N= 38).
(C) Specialty that made the ﬁnal diagnosis of Gaucher disease
(N= 116).
A. Mehta et al. Molecular Genetics and Metabolism xxx (xxxx) xxx–xxx
6
with results from the patient and physician surveys reported in the present
article, and will inform the second phase of the GED-C, the development of
an online assessment algorithm to help non-specialists identify patients at
risk of GD.
In conclusion, this publication presents ﬁndings from GD expert
physicians and GD patients that highlight an ongoing need for im-
provement in disease awareness among non-specialists. Data from both
surveys are consistent in demonstrating the occurrence of diagnostic
delays owing to misdiagnoses and the involvement of multiple spe-
cialties in making a diagnosis. A lack of awareness of the early signs and
symptoms of GD among non-specialist physicians may contribute to
misdiagnoses, delayed diagnoses and unnecessary diagnostic proce-
dures, as well as potentially resulting in the development of irreversible
complications. These ﬁndings highlight a continuing need for practical
and robust guidance on the diﬀerential diagnosis of GD to support non-
specialists in reaching a timely and deﬁnitive diagnosis. Work by
groups such as GED-C may help address this unmet need.
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